KB-1654

6F7-hIgG1

49379

Home » 6F7-hIgG1

Background of 6F7-hIgG1

Trop2 is a type I cell surface glycoprotein, which is limited in normal tissues but highly expressed in human tumor tissues. Overexpression of TROP2 can promote the growth, proliferation and metastasis of tumor cells. This differentiated expression of TROP2 protein makes it a new target for researchers to develop antibody-coupled drugs. DM001 is an BsAb based ADC targeting two tumor associated antigens: epidermal growth factor receptor (EGFR) and human trophoblast surface antigen 2 (TROP2).

Specifications

Catalog Number	KB-1654
Antibody Name	6F7-hIgG1
Isotype	Human IgG1, kappa
FC Muations	WT
Target	TROP2
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C;Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM001 in Patients With Advanced Solid Tumors
AACR 2023: A first-in-class anti-TROP2/EGFR bispecific antibody-drug conjugate, DM001, exhibits potent anti-tumor efficacy